MaxCyte, Inc. Common Stock Stock Prediction
AI-powered sentiment analysis and prediction trends for MXCT, updated each market day.
MXCT AI Sentiment
AI predicts MaxCyte, Inc. Common Stock stock is likely to increase over the next 10 market days.
Prediction date: April 30, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About MaxCyte, Inc. Common Stock
MaxCyte Inc is a life sciences company focused on advancing the discovery, development, and commercialization of next-generation cell therapies. It uses its proprietary cell engineering technology platform to support biotechnology and pharmaceutical customers in cell therapy, gene editing, immuno-oncology, and biologic development. It operates in one segment: cell engineering technology, which generates revenue mainly from product sales, licenses, research and clinical license fees, and program-related revenues as its SPL customers achieve development and regulatory milestones. Its platform, the ExPERT Platform, is based on Flow Electroporation technology designed to efficiently and safely modify human cells with high efficiency, low cytotoxicity, and scalability for clinical use.
Sector
Exchange
Market Cap
$92,071,806
Cap Tier
Employees
91
Headquarters
ROCKVILLE, MD
Listed Since
Dec. 5, 2019
Website
MXCT Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
MXCT Volatility
MaxCyte, Inc. Common Stock has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
